Back

Arcutis Biotherapeutics Inc

Ticker: ARQT ISIN: US03969K1088
Add to portfolio Portfolio analysis in 2min
Stock Mid-cap High beta Trading above 200-day average Near 52-week high
Market cap
$2.02B
Forward P/E
0.00
Profit margin
-71.25%
Revenue growth QoQ
4.28%
Beta
1.49
$24.78 -1.20%
Price as of 2026-08-24 · NASDAQ

Performance by timeframe

Rolling returns
1 Month -10.99%
6 Months -8.15%
1 Year +57.93%
5 Years +3.79% p.a.+20.41%
Since inception +1.97% p.a.+13.67%
Calendar year returns
YTD -14.67%
2025 +108.47%
2024 +331.27%
2023 -78.18%
2022 -28.64%
2021 -26.27%

Key stats

Market cap
2.02B
Beta
1.49
52-week range
6.99 - 17.70
50-day MA
13.75
200-day MA
11.16
Section 1

Business overview

Company profile data from fundamentals.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Sector Healthcare
Industry Biotechnology
Country United States
Exchange NASDAQ
Section 2

Financial quality

Above-average volatility

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -1.14%
ROA -23.25%
Profit margin -71.25%
Operating margin -10.70%
Revenue/share TTM 1.62
Revenue TTM 196.54M
EBITDA -125.80M
Gross profit TTM 177.41M
Beta 1.49

Valuation

Trailing P/E 0.00
Forward P/E 0.00
P/B 12.81
P/S 10.27
EV/EBITDA -2.04
EV/Revenue 9.67
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) -0.67
Quarterly earnings growth 0.00%
Revenue TTM 196.54M
Reported quarters 24
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0.00%
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $19.12
Analyst rating 4.375

Ownership & short interest

Shares outstanding 118.64M
Shares float 85.25M
Institutional ownership 112.30%
Insider ownership 2.02%
Short ratio 8.42
Short % of float 20.55%

Details

Instrument metadata and source update timestamps.

Symbol ARQT
Name Arcutis Biotherapeutics Inc
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US03969K1088
Country USA
Code + exchange ARQT.NASDAQ
Fundamentals updated 2025-03-23

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.